What Are Analysts Report About Verastem, Inc. (VSTM)

Lpl Finance Ltd holds 0% of its portfolio in Verastem Inc (NASDAQ:VSTM) for 17,852 shares. The institutional investor owned 373,420 shares of the biopharmaceutical company's stock after selling 700 shares during the period. TFS Capital LLC purchased a new position in shares of Verastem during the first quarter valued at approximately $113,000. Finally, Renaissance Technologies LLC boosted its position in Verastem by 13.6% in the fourth quarter.

Verastem Inc (NASDAQ:VSTM) stock reached a 1-year peak price of $4.67. Fmr Lc owns 0% invested in Verastem Inc (NASDAQ:VSTM) for 901,200 shares. Currently, the stock has a 1 Year Price Target of $4.38.

Verastem Inc (NASDAQ:VSTM) now has a trailing P/E of -3.68 while its forward P/E according to Thomson Reuters is -2.84. Renaissance Technologies LLC now owns 1,022,200 shares of the biopharmaceutical company's stock worth $1,145,000 after buying an additional 122,600 shares during the period.

Verastem, Inc. (VSTM) has the market capitalization of $107.37 Million. The share price has moved backward from its 20 days moving average -8.99% and negatively from its 50 days moving average -9.91%. The Company Touched its 52-Week High on 07/12/17 and 52-Week Low on 12/06/16.

Verastem Inc (VSTM) opened at 3.9801 on Thursday. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting analysts' consensus estimates of ($0.35). If you are reading this piece on another website, it was stolen and republished in violation of USA & worldwide trademark & copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/verastem-inc-nasdaqvstm-upgraded-to-buy-by-zacks-investment-research/1188753.html. Out of the analyst recommendations 1 rate Verastem Inc (NASDAQ:VSTM) stock a Buy, 2 rate the stock Outperform, 2 rate Hold, 0 rate Underperform and 0 recommend a Sell. Zacks Investment Research's target price suggests a potential downside of 8.31% from the stock's current price. Cantor Fitzgerald reiterated a hold rating and issued a $2.00 target price on shares of Verastem in a report on Thursday, June 8th.

Verastem, Inc. (VSTM) belonging to the Healthcare sector has surged 0.73% and closed its last trading session at $4.12. Jefferies Group LLC restated a "hold" rating and set a $1.50 target price on shares of Verastem in a research report on Wednesday, June 28th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock.

In related news, Director Timothy J. Barberich purchased 30,000 shares of the stock in a transaction that occurred on Monday, May 15th. The stock has a beta value of 2.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Average estimation for the current quarter has been provided by 5 analysts. The company discovers, researches, and develops new medicines for the treatment of major cancers such as breast cancer.

Verastem, Inc is a biopharmaceutical company. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584.